

SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor ,SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & SIX MONTHS ENDED 30th SEPTEMBER, 2021.

Rs. In Lakhs

PART -	I	STANDALONE							
SI. No.	PARTICULARS	For the Quarter Ended			For 6 Mon	For the year ended			
	TANTIGOLANG	30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021		
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	Audited		
		(1)	(2)	(3)	(4)	(5)	(6)		
1	Income								
	Revenue from operations	30,098.83	26,380.13	23,738.81	56,478.96	47,562.05	100,971.8		
	Other Income	3,833.50	578.29	35.68	4,411.79	609.59	1,423.70		
	Total income	33,932.33	26,958.42	23,774.49	60,890.75	48,171.64	102,395.5		
2	Expenses								
	a) Cost of materials consumed	11,885.90	9,183.96	7,717.95	21,069.86	14,318.22	31,031.5		
	b) Purchases of stock-in-trade	-	-	-	-	-	-		
	c) Changes in inventories of finished								
	goods, work-in-progress and stock-in-								
	trade	(2,628.34)	(1,508.91)	(355.65)	(4,137.25)	118.99	(837.30		
	d) Employee benefits expense	2,319.43	2,115.89	2,092.90	4,435.32	3,837.32	7,623.30		
	e) R & D expense	366.94	235.24	381.42	602.18	689.27	1,105.7		
	f)Finance costs	117.51	212.55	264.31	330.06	536.31	914.37		
	g) Depreciation and amortisation								
	expenses	917.70	899.33	750.02	1,817.03	1,456.36	3,163.58		
	h) Manufacturing Expenses	4,373.88	3,884.83	2,970.64	8,258.71	5,359.35	13,378.9		
	i) Other Expenses	1,603.51	1,007.47	1,144.20	2,610.98	2,289.43	4,617.49		
	Total expenses	18,956.53	16,030.36	14,965.79	34,986.89	28,605.25	60,997.6		
3	Profit before exceptional items &	14,975.80	10,928.06	8,808.70	25,903.86	19,566.39	41,397.9		
4	Tax (1-2) Exceptional Items	14,975.00	10,926.06	8,808.70	25,905.66	19,500.59	41,377.7		
5	Profit before Tax (3-4)	- 14,975.80	10,928.06	8,808.70	25,903.86	19,566.39	41,397.9		
6	Tax Expenses	14,975.00	10,926.06	6,808.70	25,905.66	19,500.59	41,377.7		
U	a) Current tax	3,278.01	2,716.35	2,163.92	5,994.36	4,892.64	10,171.5		
	b) Deferred tax	178.03	67.59	111.78	245.62	17.75	361.7		
	Net Profit/ (Loss) for the	170.03	07.57	111.70	243,02	17.73	301.77		
7	period/year(5-6)	11,519.76	8,144.12	6,533.00	19,663.88	14,656.00	30,864.6		
8	Other Comprehensive Income	11,21111	-,	-	11,122,022	-	22,223,0		
_	(i) Items that will not be								
8.a	reclassified to profit or loss	(27.98)	(27.96)	(27.32)	(55.94)	(54.65)	(111.8		
	(ii) Income tax relating to items	, ,	, ,	, ,		, ,	·		
	that will not be reclassified to								
	profit or loss	7.05	7.03	6.88	14.08	13.76	28.1		
8.b	(i) Items that will be reclassified								
0.0	to profit or loss	-	-	-	-	-	-		
	(ii) Income tax relating to items								
	that will be reclassified to profit								
	or loss	-	-	-	-	-	-		
	Total other Comprehensive Income		(22.22)	455.44					
	•	(20.93)	(20.93)	(20.44)	(41.86)	(40.89)	(83.70		
9	Total Comprehensive Income for	44 400 03	0.422.40	(542 54	40 (22 02	4474544	20.700.00		
40	the period (7+8)	11,498.83	8,123.19	6,512.56	19,622.02	14,615.11	30,780.99		
10	Paid-up equity share capital	2,545.65	2,545.65	2,545.65 Re.1.00	2,545.65	2,545.65 Re.1.00	2,545.6! Re.1.00		
11	Face Value of the Share Other Equity	Re.1.00	Re.1.00	Ke. 1.00	Re.1.00	Ke. 1.00			
11	Earning Per Share (EPS) (Face	_	-	-	_	_	103,972.6		
12	value of Rs. 1/- each)								
	a) Basic	4.53	3.20	2.57	7.72	5.76	12.1		
	b) Diluted	4.53	3.20	2.57	7.72	5.76	12.12		
	s, shace	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)		
		(not annualiseu)	(110c amidatised)	(1.5c amidansed)	(iioc aimaansea)	(oc amidansed)	, amuansec		

PART -	II	CONSOLIDATED					
SI. No.	PARTICULARS	Fo	r the Quarter En	ded	For 6 Mor	For the year ended	
31. NO.	PARTICULARS	30/09/2021	30/06/2021	30/09/2020	30/09/2021	30/09/2020	31/03/2021
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	Audited
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income	30,098.83	26,380.13	23,738.81	56,478.96	47,562.05	100,971.85
	Revenue from operations	•					
	Other Income	504.11	578.29	35.68	1,082.40	609.59	1,423.70
2	Total income	30,602.94	26,958.42	23,774.49	57,561.36	48,171.64	102,395.55
2	Expenses a) Cost of materials consumed b) Purchases of stock-in-trade	11,885.90 -	9,183.96 -	7,717.95 -	21,069.86	14,318.22 -	31,031.50
	 c) Changes in inventories of finished goods, work-in-progress and stock-in- trade 	(2,628.34)	(1,508.91)	(355.65)	(4,137.25)	118.99	(837.30)
	d) Employee benefits expense	2,319.43	2,115.89	2,092.90	4,435.32	3,837.32	7,623.30
	e) R & D expense	366.94	235.24	381.42	602.18	689.27	1,105.75
	f)Finance costs	117.51	212.55	264.31	330.06	536.31	914.37
	g) Depreciation and amortisation						
	expense	917.70	899.33	750.02	1,817.03	1,456.36	3,163.58
	h) Manufacturing Expenses	4,373.88	3,884.83	2,970.64	8,258.71	5,359.35	13,378.94
	i) Other Expenses	1,603.52	1,008.18	1,144.56	2,611.70	2,292.39	4,621.60
	Total expenses	18,956.54	16,031.07	14,966.15	34,987.61	28,608.21	61,001.74
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	11,646.40	10,927.35	8,808.34	22,573.75	19,563.43	41,393.81
4	Add: Share of profit/(Loss) of Associates.	1,746.33	2,364.90	875.26	4,111.23	1,907.02	5,373.60
5	Profit before exceptional items , Tax (3+4)	13,392.73	13,292.25	9,683.60	26,684.98	21,470.45	46,767.41
6 7 8	Exceptional Items Profit before Tax (5-6) Tax Expenses	13,392.73	- 13,292.25	9,683.60	26,684.98	21,470.45	46,767.41
	a) Current tax	3,516.22	2,716.35	2,163.92	6,232.57	4,892.64	10,171.51
	b) Deferred tax	178.03	67.59	111.78	245.62	17.75	361.72
9	Net Profit/ (Loss) for the period/year(7-8)	9,698.48	10,508.31	7,407.90	20,206.79	16,560.06	36,234.18
10	Other Comprehensive Income						
10.a	(i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items	(27.98)	(27.96)	(27.32)	(55.94)	(54.65)	(111.85)
	that will not be reclassified to profit or loss	7.05	7.03	6.88	14.08	13.76	28.15
10.b	(i) Items that will be reclassified to profit or loss (ii) Income tax relating to items	-	-	-	-	-	
	that will be reclassified to profit or loss	-	-		-		
	Total other Comprehensive Income	(20.93)	(20.93)	(20.44)	(41.86)	(40.89)	(83.70)
11	Total Comprehensive Income for the period (9 + 10)	9,677.55	10,487.38	7,387.46	20,164.93	16,519.17	36,150.48
12	Paid-up equity share capital	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65
13	Face Value of the Share Other Equity	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00 115,535.18
14	Earning Per Share (EPS) (Face value of Rs. 1/- each)			_		_	
	a) Basic -	3.81	4.13	2.91	7.94	6.51	14.23
	b) Diluted	3.81	4.13	2.91	7.94	6.51	14.23
		(not annualised)	(annualised)				

Notes 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 6th November, 2021. The above results have been subjected to limited review by the statutory auditors of the company

2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.

3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma, Inc., USA and associate Rising Pharma Holding, Inc., USA

4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.

5) The COVID-19 continuous to impact the business and research operations in India and our Wholly Owned Subsidiary, Suven Pharma, Inc., USA. Apart from the above the shortage or non- availability of vessels leading to delay in shipments, increase in transportation and distribution costs and timely non availability of materials with increase in materials costs are impacting our operations and profiability.

6) The other Income (Standalone figures) includes an amount of Rs.3329.39 Lakhs pertaining to the Dividends received form our Subsiadary. And also the Current tax (Standalone figures) includes an amount of Rs.491.72 Lakhs tax paid on Such Dividend by our subsidiary.

7) The corresponding previous period figures have been regrouped/reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD

VENKAT JASTI Chairman & MD DIN: 00278028

Place: Hyderabad Date: 6th November,2021



SUVEN PHARMACEUTICALS LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Statement of Assets & Liabilities

Rs.in Lakhs

1					Rs.in Lakhs		
	Particulars	Standalone as at		Consolida			
ļ.		30/09/2021	31/03/2021	30/09/2021	31/03/2021		
Α	ASSETS	Un-Audited	Audited	Un-Audited	Audited		
1	Non-current assets						
	(a) Property,Plant and Equipment	53,470.55	43,706.51	53,470.55	43,706.51		
	(b) Capital Work-in-Progress	1,671.98	9,614.91	1,671.98	9,614.91		
	(c) Other Intangible Assets	243,50	241.75	243,50	241.75		
	(d) Intangible assets under development	-	17.30	-	17.30		
	(e) Right of use of assets	198.47	167.53	198.47	167.53		
	(f) Financial Assets						
	I. Investments	24,564.73	24,564.73	36,588.14	36,119.40		
	II.Loans	6.20	6.20	6.20	6.20		
	III.Other Financial Assets	514.06	495.18	514.06	495.18		
	(g) Deferred tax assets (net)	-	-	-	-		
	(h) Other non current assets	575.82	599.21	575.82	599.21		
	Total Non-Current assets	81,245.31	79,413.32	93,268.72	90,967.99		
2	Current assets						
	(a) Inventories	26,462.27	20,108.04	26,462.27	20,108.04		
	(b) Financial Assets			-			
	I. Investments	20,947.09	18,059.38	20,947.09	18,059.38		
	II.Trade Receivables	16,390.24	10,238.22	16,390.24	10,238.22		
	III.Cash and Cash equivalents	1,600.79	709.14	1,733.78	718.22		
	IV. Bank balances otherthan (III) above	258.45	247.10	258.45	247.10		
	V. Loans	19.49	21.78	19.49	21.78		
	VI. Other Financial assets	-	-	-	-		
	(c) Current Tax asset(net)	-	224.67	-	224.67		
	(d) Other current assets	7,172.13	6,861.11	7,172.14	6,861.11		
	Total Current assets	72,850,46	56,469.44	72,983.46	56,478.52		
		, .	,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	, ,		
	TOTAL - ASSETS	154,095,77	135,882.76	166,252.18	147,446.51		
R	EQUITY AND LIABILITIES	,	,	,	,		
	EQUITY						
Ι.	(a) Equity Share Capital	2,545.65	2,545.65	2,545.65	2,545.65		
	(b) Other Equity	121,049.05	103,972.68	133,205.45	115,535.18		
	Equity attributable to owners of the company	123,594.70	106,518.33	135,751.10	118,080.83		
2	' '	123,374.70	100,510.55	133,731.10	110,000.03		
	-						
	(a) Financial Liabilities	405.46	72.00	105.46	72.00		
	I. Lease Liability	105.46	73.90	105.46	73.90		
	II. Borrowings	3,507.94	3,559.09	3,507.94	3,559.09		
	(b) Provisions	664.60	664.60	664.60	664.60		
	(c) Deferred tax Liabilities (net)	3,324.84	3,093.29	3,324.84	3,093.29		
	(d) Other non current liabilities	7 400 6 1	7 200 00	7 100 61	7 200 55		
	Total non-current liabilities	7,602.84	7,390.88	7,602.84	7,390.88		
	Current liabilities						
	(a) Financial Liabilities						
	I. Lease Liability	109.09	106.82	109.09	106.82		
	II. Borrowings	9,345.21	10,563.76	9,345.21	10,563.76		
	III. Trade payables			-			
	a) To Micro & Small Enterprises	920.16	996.25	920.16	996.25		
	b) Other than Micro & Small Enterprises	8,901.32	7,296.89	8,901.32	7,296.89		
	IV. Other Financial Liabilities	2,481.38	2,522.75	2,481.39	2,524.00		
	(b) Current Tax liabilities (Net)	127.21	-	127.21	-		
	(c) Provision Employee benefits	314.90	260.72	314.90	260.72		
	(d) Other Current liabilities	698.96	226.36	698.96	226.36		
		22,898.23	21,973.55	22,898.24	21,974.80		
	Total Liabilities	30,501.07	29,364.43	30,501.08	29,365.68		
	TOTAL - EQUITY AND LIABILITIES	154,095.77	135,882.76	166,252.18	147,446.51		
\vdash	•	•	-	•	<u> </u>		

For Suven pharmaceuticals Ltd

Place : Hyderabad

Date: 6th November, 2021

Venkat Jasti Chairman & MD

SUVEN PHARMACEUTICALS LIMITED Standalone Statement of Cash flows for the period ended 30th September, 2021 (All amounts in Indian Rupees in Lakhs, unless otherwise stated) For the period ended For the period ended **Particulars** 30th September 2021 30th September 2020 A. Cash flow from operating activities 25903.86 19,566.39 Profit before tax Adjustments : Depreciation and amortisation expense 1775.48 1,439.72 Interest Income (16.60)(18.05)Finance Cost 330.06 536.30 Gain on sale of Current Investment (438.34)(155.39)Dividend received from WOS (3329.39)Effects of foreign exchange rates (Unrealized) (51.83)(61.44)Loss/(Profit) on disposal of Property, plant & equipment (0.06)Operating profit before working capital changes 24173.18 21307.53 Adjustments for (Increase)/decrease in operating assets (6060.03) 1,087.40 Trade Receivables (6354.23) (2,261.60)Inventories Other non current assets (30.94)819.47 Other current assets (308.49)(3,222.96)Adjustments for Increase/(decrease) in operating liabilities 917.70 1519.94 **Trade Payables** Short term provision (1.75)223.34 Other financial liabilities 642.47 (615.60)462.45 Other current liabilities (133.46)Cash generated from operating activities 14042.59 18121.82 Income taxes paid (net of refunds) (5642.47)(4,059.96)Net Cash flows from operating activities (A) 8400.12 14061.86 B. Cash flow from Investing activities (4245.15)(6,284.76)Payments for Purchase of property, plant and equipment Proceeds from sale of Property, plant & equipment 0.06 3329.39 Dividend received from WOS Fixed deposits/margin money-placed/matured (18.89)(3,888.02)Sale/(purchase) of mutual funds (2449.37)(7.70) (199.84) Bank balances not considered as cash and cash equivalents Net cash flow from /(used in) investing activities (B) (3391.65) (10,372.62) C. Cash flows from financing activities (125.91)(3,623.43)(Repayment)/Proceeds from long term borrowings (Repayment)/Proceeds from short term borrowings (1167.91) 416.49 Other non current financial assets 1.37 Other current financial assets 2.30 (9.29)Changes In Lease Liability 94.64 33.83 **Finance Cost** (330.06)(536.30)Interest received 16.60 18.05 Dividends paid to equity holders (including dividend distribution tax) (2545.65)Net cash flow from /(used In) financing activities (C) (3,638.47) (4116.80)(A+B+C) 891.68 50.77 Net increase/(decrease) in cash and cash equivalents Cash and cash equivalents as at the beginning of the year 709.14 1,157.68 Effect of exchange differences on restatement on foreign currency cash & (0.03)cash equivalents 1.71 Cash and cash equivalents at the end of the year 1600.79 1210.16 Cash and cash equivalents 1600.79 1,210.16 1,210.16 Balances per statement of cash flows 1600.79

For Suven Pharmaceuticals Ltd

Venkateswarlu Jasti Chairman & M D DIN: 00278028

Place: Hyderabad
Date: 06th November,2021

SUVEN PHARMACEUTICALS LIMITED Consolidated Statement of Cash flows for the period ended 30th September, 2021 (All amounts in Indian Rupees in Lakhs, unless otherwise stated) For the period ended For the period ended **Particulars** 30th September 2021 30th September 2020 A. Cash flow from operating activities 26684.97 21,470.45 Profit before tax Adjustments: Depreciation and amortisation expense 1775.48 1,439.72 Interest Income (16.60) (18.05) Finance Cost 330.06 536.30 Gain on sale of Current Investment (438.34)(155.39)(61.44) (51.83)Effects of foreign exchange rates (Unrealized) Loss/(Profit) on disposal of Property, plant & equipment (0.06)Operating profit before working capital changes 28283.68 23211.59 Adjustments for (Increase)/decrease in operating assets 1,087.40 Trade Receivables (6060.03)Inventories (6354.23)(2,261.60)Other non current assets (30.94)819.47 (308.49)(3,222.96)Other current assets Adjustments for Increase/(decrease) in operating liabilities 1519.94 917.70 **Trade Payables** Short term provision (1.75)223.34 641.21 (619.98)Other financial liabilities Other current liabilities 462.45 (133.46)20021.50 Cash generated from operating activities 18151.84 Income taxes paid (net of refunds) (5880.68) (4,059.96)Net Cash flows from operating activities (A) 12271.16 15961.54 B. Cash flow from Investing activities (6,284.76) Payments for Purchase of property, plant and equipment (4245.15)Proceeds from sale of Property, plant & equipment 0.06 (1,907.02)Changes in Investments (468.73)Fixed deposits/margin money-placed/matured (18.89)(3,888.02) (2449.37) Sale/(purchase) of mutual funds Foreign currency translation reserve 50.99 (0.14)Bank balances not considered as cash and cash equivalents (7.70)(199.84)(7138.78) (12279.78) Net cash flow from /(used in) investing activities (B) C. Cash flows from financing activities (125.91)(Repayment)/Proceeds from long term borrowings (3,623.43)(1167.91)416.49 (Repayment)/Proceeds from short term borrowings Other non current financial assets 0.00 1.37 Other current financial assets 2.30 (9.29)Changes In Lease Liability 33.83 94.64 (536.30) **Finance Cost** (330.06)Interest received 16.60 18.05 Dividends paid to equity holders (including dividend distribution tax) (2545.65)Net cash flow from /(used In) financing activities (C) (4116.80)(3638.47)Net increase/(decrease) in cash and cash equivalents (A+B+C) 1015.58 43.29 Cash and cash equivalents as at the beginning of the year 1,169.53 718.23 Effect of exchange differences on restatement on foreign currency cash & cash equivalents (0.03)1.71 Cash and cash equivalents at the end of the year 1733.78 1214.53 Cash and cash equivalents 1733.78 1,214.53 Balances per statement of cash flows 1733.78 1214.53

For Suven Pharmaceuticals Ltd

Venkateswarlu Jasti Chairman & M D DIN: 00278028

Place: Hyderabad Date: 06th November,2021